Xeltis is dedicated to transforming the standards of care in cardiovascular treatment by developing the first-ever bioabsorbable cardiovascular valves and vessels designed to allow Endogenous Tissue Restoration (ETR). Xeltis is striving to enable ETR to potentially help reduce the risk of complications and repeated interventions in patients requiring cardiovascular valves and vessels replacement, for them to live better, longer lives at lower cost for the healthcare systems.